Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $185 to $200.
Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $185 to $200.